Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7698345rdf:typepubmed:Citationlld:pubmed
pubmed-article:7698345lifeskim:mentionsumls-concept:C0007452lld:lifeskim
pubmed-article:7698345lifeskim:mentionsumls-concept:C0376604lld:lifeskim
pubmed-article:7698345lifeskim:mentionsumls-concept:C0034830lld:lifeskim
pubmed-article:7698345lifeskim:mentionsumls-concept:C0133873lld:lifeskim
pubmed-article:7698345lifeskim:mentionsumls-concept:C0439799lld:lifeskim
pubmed-article:7698345lifeskim:mentionsumls-concept:C1533157lld:lifeskim
pubmed-article:7698345pubmed:issue1lld:pubmed
pubmed-article:7698345pubmed:dateCreated1995-5-2lld:pubmed
pubmed-article:7698345pubmed:abstractTextWe have studied the contribution of P-type voltage-dependent Ca2+ channels to both catacholamine (CA) and ATP secretion from bovine chromaffin cells induced by high K+ or nicotine using omega-agatoxin IVA, a selective blocker of P-type voltage-dependent Ca2+ channels. We found that high K+ (75 mM) induced the release of about 13% of norepinephrine, 5% epinephrine and 11% ATP, and that omega-agatoxin (100 nM) did not affect this secretion. However, both nicotine-induced CA and ATP secretion were significantly blocked (about 50%) by omega-agatoxin IVA (100 nM). In addition, this toxin also reversibly blocked (about 70%) the inward current induced by nicotine in bovine chromaffin cells. The results suggest that, besides its known action of blocking P-type voltage-dependent channels, omega-agatoxin is a potent and reversible blocker of the nicotinic receptor channel in chromaffin cells, and that this action would explain the blockade of nicotine-induced secretion.lld:pubmed
pubmed-article:7698345pubmed:languageenglld:pubmed
pubmed-article:7698345pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7698345pubmed:citationSubsetIMlld:pubmed
pubmed-article:7698345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7698345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7698345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7698345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7698345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7698345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7698345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7698345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7698345pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7698345pubmed:statusMEDLINElld:pubmed
pubmed-article:7698345pubmed:monthMarlld:pubmed
pubmed-article:7698345pubmed:issn0014-5793lld:pubmed
pubmed-article:7698345pubmed:authorpubmed-author:GranjaRRlld:pubmed
pubmed-article:7698345pubmed:authorpubmed-author:CeñaVVlld:pubmed
pubmed-article:7698345pubmed:authorpubmed-author:González-Garc...lld:pubmed
pubmed-article:7698345pubmed:authorpubmed-author:Fernández-Fer...lld:pubmed
pubmed-article:7698345pubmed:authorpubmed-author:IzaguirreVVlld:pubmed
pubmed-article:7698345pubmed:issnTypePrintlld:pubmed
pubmed-article:7698345pubmed:day27lld:pubmed
pubmed-article:7698345pubmed:volume362lld:pubmed
pubmed-article:7698345pubmed:ownerNLMlld:pubmed
pubmed-article:7698345pubmed:authorsCompleteYlld:pubmed
pubmed-article:7698345pubmed:pagination15-8lld:pubmed
pubmed-article:7698345pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7698345pubmed:meshHeadingpubmed-meshheading:7698345-...lld:pubmed
pubmed-article:7698345pubmed:meshHeadingpubmed-meshheading:7698345-...lld:pubmed
pubmed-article:7698345pubmed:meshHeadingpubmed-meshheading:7698345-...lld:pubmed
pubmed-article:7698345pubmed:meshHeadingpubmed-meshheading:7698345-...lld:pubmed
pubmed-article:7698345pubmed:meshHeadingpubmed-meshheading:7698345-...lld:pubmed
pubmed-article:7698345pubmed:meshHeadingpubmed-meshheading:7698345-...lld:pubmed
pubmed-article:7698345pubmed:meshHeadingpubmed-meshheading:7698345-...lld:pubmed
pubmed-article:7698345pubmed:meshHeadingpubmed-meshheading:7698345-...lld:pubmed
pubmed-article:7698345pubmed:meshHeadingpubmed-meshheading:7698345-...lld:pubmed
pubmed-article:7698345pubmed:meshHeadingpubmed-meshheading:7698345-...lld:pubmed
pubmed-article:7698345pubmed:meshHeadingpubmed-meshheading:7698345-...lld:pubmed
pubmed-article:7698345pubmed:meshHeadingpubmed-meshheading:7698345-...lld:pubmed
pubmed-article:7698345pubmed:meshHeadingpubmed-meshheading:7698345-...lld:pubmed
pubmed-article:7698345pubmed:meshHeadingpubmed-meshheading:7698345-...lld:pubmed
pubmed-article:7698345pubmed:year1995lld:pubmed
pubmed-article:7698345pubmed:articleTitleomega-Agatoxin IVA blocks nicotinic receptor channels in bovine chromaffin cells.lld:pubmed
pubmed-article:7698345pubmed:affiliationDepartamento de Farmacología, Universidad de Alicante, Spain.lld:pubmed
pubmed-article:7698345pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7698345pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7698345lld:pubmed